KemPharm Inc. (KMPH) Cut to Hold at Zacks Investment Research
According to Zacks, “KemPharm Inc. is a specialty pharmaceutical company which is engaged in the discovery and development of new molecular entity prodrugs. Its product candidates include KP201/APAP, KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder and KP303 for the treatment of central nervous system disorders, which are in preclinical trail stage. The Company through its LAT platform technology generate prodrug. KemPharm Inc. is based in CORALVILLE, United States. “
A number of other brokerages have also commented on KMPH. Canaccord Genuity reissued a buy rating on shares of KemPharm in a report on Wednesday, August 10th. Oppenheimer Holdings Inc. restated a buy rating and issued a $11.00 target price on shares of KemPharm in a research note on Tuesday, June 14th.
KemPharm (NASDAQ:KMPH) opened at 4.10 on Wednesday. The company’s 50-day moving average price is $4.58 and its 200 day moving average price is $7.35. The firm’s market capitalization is $60.05 million. KemPharm has a 12 month low of $3.52 and a 12 month high of $20.60.
KemPharm (NASDAQ:KMPH) last posted its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.94) by $0.36. On average, equities research analysts predict that KemPharm will post ($1.78) earnings per share for the current year.
In other news, EVP Daniel L. Cohen acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 6th. The shares were acquired at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the purchase, the executive vice president now owns 1,310 shares in the company, valued at $6,222.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 22.80% of the stock is owned by corporate insiders.
A number of institutional investors have recently bought and sold shares of KMPH. Parkwood LLC bought a new stake in KemPharm during the second quarter valued at about $107,000. William Harris Investors Inc. increased its stake in KemPharm by 93.3% in the second quarter. William Harris Investors Inc. now owns 30,891 shares of the specialty pharmaceutical company’s stock valued at $123,000 after buying an additional 14,911 shares in the last quarter. Menta Capital LLC increased its stake in KemPharm by 11.3% in the first quarter. Menta Capital LLC now owns 11,410 shares of the specialty pharmaceutical company’s stock valued at $165,000 after buying an additional 1,154 shares in the last quarter. BlackRock Institutional Trust Company N.A. increased its stake in KemPharm by 4.9% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 35,485 shares of the specialty pharmaceutical company’s stock valued at $515,000 after buying an additional 1,653 shares in the last quarter. Finally, Spark Investment Management LLC increased its stake in KemPharm by 195.1% in the second quarter. Spark Investment Management LLC now owns 141,109 shares of the specialty pharmaceutical company’s stock valued at $561,000 after buying an additional 93,284 shares in the last quarter. Institutional investors and hedge funds own 42.65% of the company’s stock.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for KemPharm Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm Inc. and related companies with MarketBeat.com's FREE daily email newsletter.